TRAF3-Mediated Microglial Reprogramming by Time-Interferential Stimulation Enables Spatioselective Neuronal Rescue Post-Ischemia-Reperfusion 

Technical Summary: TRAF3-Mediated Microglial Reprogramming by Time-Interferential Stimulation Enables Spatioselective Neuronal Rescue Post-Ischemia-Reperfusion

Problem Statement
Despite the success of mechanical thrombectomy and intravenous t-PA in achieving recanalization for ischemic stroke, patients frequently suffer from Cerebral Ischemia-Reperfusion Injury (CIRI). This secondary injury involves an oxidative and inflammatory cascade that current therapies fail to adequately mitigate due to a narrow therapeutic window and limited neuroprotection. A central driver of CIRI is neuroinflammation mediated by microglia, which can transition to a pro-inflammatory M1 state, driving neuronal death via pyroptosis. While non-invasive neuromodulation techniques like Temporal Interference Stimulation (TIS) have shown promise in neurodegenerative models, the specific molecular circuitry through which TIS confers neuroprotection in CIRI, particularly regarding microglial polarization and pyroptosis, remains undefined. Furthermore, the role of Tumor Necrosis Factor Receptor-Associated Factor 3 (TRAF3) in orchestrating this specific injury pathway and its susceptibility to TIS modulation has not been explored.

Methodology
The study employed a multimodal approach combining in vivo and in vitro models to dissect the TIS-TRAF3 signaling nexus:

• In Vivo Model: Adult male Sprague-Dawley rats underwent 90-minute Middle Cerebral Artery Occlusion (MCAO) followed by reperfusion. Immediately upon reperfusion, animals received daily 30-minute sessions of TIS (2.00/2.04 kHz carrier frequencies, 1 mA envelope) or sham stimulation for 7 days. To investigate the role of TRAF3, an AAV-siTRAF3 vector was used to knock down TRAF3 in vivo.
• In Vitro Model: BV2 microglial cells were subjected to Hypoxic-Ischemic Deprivation (HIE) to simulate CIRI. Cells were transfected with TRAF3-specific siRNAs or overexpression vectors to modulate TRAF3 levels.
• Assessments: Outcomes were evaluated using:
  • Histology/Immunofluorescence: NeuN (neuronal survival), GFAP (astrocyte activation), Iba1 (microglial activation), CD86/CD206 (M1/M2 polarization), and TUNEL (apoptosis).
  • Molecular Biology: Western blotting for TRAF3, p-TBK1, TBK1, Cleaved-caspase-1, and NLRP3; Co-immunoprecipitation (Co-IP) to verify protein-protein interactions; qPCR for mRNA levels.
  • Functional Assays: ELISA for cytokine release (IL-1β, IL-18), EdU staining for proliferation, and flow cytometry for apoptosis.
  • Statistical Analysis: One-way ANOVA with LSD-t post-hoc tests.

Key Contributions and Results

1. TIS Neuroprotection and Glial Modulation:

   • TIS significantly increased neuronal survival (NeuN density) by 38% compared to the sham-stimulated CIRI model.
   • It reduced pathological glial activation, decreasing GFAP (astrocytes) and Iba1 (microglia) coverage by 34% and 29%, respectively.
   • TIS shifted microglial polarization from the pro-inflammatory M1 state (CD86-high) to the anti-inflammatory M2 state (CD206-high), reducing IL-1β levels by 46%.

2. TRAF3 as a Critical Regulator:

   • Polarization: TRAF3 knockdown mimicked the beneficial effects of TIS, promoting M2 polarization and reducing IL-1β. Conversely, TRAF3 overexpression exacerbated M1 polarization and increased IL-18 secretion.
   • Cell Death: TRAF3 was identified as a pro-apoptotic and pro-pyroptotic driver. Silencing TRAF3 reduced HIE-induced apoptosis and pyroptosis markers (Cleaved-caspase-1, NLRP3), while overexpression augmented them.
   • Mechanism: Co-immunoprecipitation confirmed a direct physical interaction between TRAF3 and TBK1. TIS was shown to disrupt this TRAF3-TBK1 binding, thereby suppressing the downstream TRAF3-TBK1-NLRP3 pyroptotic axis.

3. Synergistic Effects:

   • The combination of TIS and TRAF3 knockdown (AAV-siTRAF3) yielded superior outcomes compared to either monotherapy. This combination further reduced hippocampal TUNEL-positive neurons by 55%, suppressed pyroptotic signaling proteins, and improved 7-day neurological scores beyond single treatments.

Significance and Claims
The paper claims to provide the first evidence that TIS acts as a non-invasive therapeutic strategy for CIRI by specifically targeting the TRAF3-TBK1-NLRP3 axis. The study posits that TIS interrupts the interaction between TRAF3 and TBK1, which re-educates microglia toward an anti-inflammatory M2 phenotype and halts pyroptotic neuronal death.

The authors assert that this work:

• Establishes TRAF3 as a tractable molecular target for non-invasive neuromodulation.
• Offers a "spatioselective" method to rescue neurons in deep brain structures (such as the hippocampus) without the need for craniotomy or the thermal risks associated with other stimulation methods.
• Bridges a critical knowledge gap regarding the molecular mechanisms of TIS in stroke, moving beyond general neuroprotection to specific pathway modulation.
• Provides a clinically translatable framework where physical stimulation (TIS) can modulate specific inflammatory cascades, potentially offering a solution for patients who miss the narrow window for thrombolysis or require adjunctive neuroprotection post-recanalization.

The study concludes that while model constraints exist (e.g., lack of aged animal models and delayed intervention windows in the preclinical phase), the findings lay a robust mechanistic foundation for extending TIS from neurodegenerative applications to ischemic cerebrovascular therapy.